Modern injected its mRNA-derived vaccine for seasonal flu into a human volunteer for the first time as part of a Phase 1/2 clinical study, the company announced Wednesday.
This is a very early test for new vaccination technology, aimed primarily at building a basic understanding of the “safety, reatogenicity and immunogenicity” of treatment, according to a Modern version. mRNA-1010, as the vaccine has been duplicated, is designed to be effective against the four most common strains of the virus including, H1N1, H3N2, Yamagata influenza B and Victoria B influenza. According to the World Health Organization, these strains cause between 3 and 5 million serious cases of influenza each year, resulting in 650,000 respiratory deaths related to the flu each year. In the United States alone, about 8 percent of the population comes with the flu every winter. The company hopes that this vaccination will prove more potent than the current 40 percent-effective 40 percent of conventional influenza vaccines.
“We are pleased to have initiated this Phase 1/2 study of mRNA-1010, our first candidate for the seasonal mRNA influenza vaccine to enter the clinic. We hope that our candidates for seasonal flu vaccination will be an important component of our future respiratory vaccine combinations, “said Stéphane Bancel, CEO of Moderna.” Combination respiratory vaccines are an important pillar of our general strategy of mRNA vaccine We believe that the advantages of mRNA vaccines include the ability to combine different antigens to protect against multiple viruses and the ability to respond rapidly to the evolution of respiratory viruses, such as influenza, SARS-CoV -2 and RSV. Our vision is to develop a combined mRNA vaccine so that people can get a shot every fall for high-effectiveness protection against the most problematic respiratory viruses. “
This vaccine was generated using the same genomic techniques that society used develop its COVID-19 treatment in 2020. The technique works by exploiting the cells of the human body to reproduce fragments of viral DNA to instigate an immune response and pressurize the body against future infections. Since this method does not require the entire virus (either weakened or dead), but rather just a birt of its genetic code, mRNA vaccines can be applied to a number of modern deadly diseases including malaria, TB – even cancer.
All products recommended by Engadget are selected by our editorial team, independent of our parent company. Some of our stories include affiliate links. If you buy something through one of these links, you can earn an affiliate commission.